Search Results - "Patard, J J"

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Porta, C, Schmidinger, M, Algaba, F, Patard, J J, Khoo, V, Eisen, T, Horwich, A

Get full text

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up by Escudier, B, Eisen, T, Porta, C, Patard, J J, Khoo, V, Algaba, F, Mulders, P, Kataja, V

Get full text

Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? by Dolley-Hitze, T, Jouan, F, Martin, B, Mottier, S, Edeline, J, Moranne, O, Le Pogamp, P, Belaud-Rotureau, M-A, Patard, J-J, Rioux-Leclercq, N, Vigneau, C

“…Background: The growth factor Angiotensin-2 signals through Angiotensin receptor type 1 (AT1-R) in a broad range of cell types and tumours and through the…”
Get full text

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma by Saroufim, A, Messai, Y, Hasmim, M, Rioux, N, Iacovelli, R, Verhoest, G, Bensalah, K, Patard, J-J, Albiges, L, Azzarone, B, Escudier, B, Chouaib, S

“…Background: Angiogenesis is essential for tumour growth and metastasis. There are conflicting reports as to whether microvessel density (MVD) using the…”
Get full text

Aortic dissection in a patient treated by sunitinib for metastatic renal cell carcinoma by Edeline, J., Laguerre, B., Rolland, Y., Patard, J.-J.

Get full text

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib by Beuselinck, B, Karadimou, A, Lambrechts, D, Claes, B, Wolter, P, Couchy, G, Berkers, J, Paridaens, R, Schöffski, P, Méjean, A, Verkarre, V, Lerut, E, de la Taille, A, Tourani, J-M, Bigot, P, Linassier, C, Négrier, S, Berger, J, Patard, J-J, Zucman-Rossi, J, Oudard, S

“…Background: There are no validated markers that predict response in metastatic renal cell cancer (RCC) patients treated with sunitinib. We aim to study the…”
Get full text

Antiviral responses of human Leydig cells to mumps virus infection or poly I:C stimulation by Le Tortorec, A., Denis, H., Satie, A-P., Patard, J-J., Ruffault, A., Jégou, B., Dejucq-Rainsford, N.

“…BACKGROUND The immuno-privileged status of the testis is essential to the maintenance of its functions, and innate immunity is likely to play a key role in…”
Get full text

De Novo Kidney Graft Tumors: Results From a Multicentric Retrospective National Study by Tillou, X., Doerfler, A., Collon, S., Kleinclauss, F., Patard, J.‐J., Badet, L., Barrou, B., Audet, M., Bensadoun, H., Berthoux, E., Bigot, P., Boutin, J.‐M., Bouzguenda, Y., Chambade, D., Codas, R., Dantal, J., Deturmeny, J., Devonec, M., Dugardin, F., Ferrière, J.‐M., Erauso, A., Feuillu, B., Gigante, M., Guy, L., Karam, G., Lebret, T., Neuzillet, Y., Legendre, C., Perez, T., Rerolle, J.‐P., Salomon, L., Sallusto, F., Sénéchal, C., Terrier, N., Thuret, R., Verhoest, G., Petit, J.

“…De novo tumors in renal allografts are rare and their prevalence is underestimated. We therefore analyzed renal cell carcinomas arising in renal allografts…”
Get full text

Prognostic significance of the mode of detection in renal tumours by Patard, J.‐J., Rodriguez, A., Rioux‐Leclercq, N., Guillé, F., Lobel, B.

“…Objective  To evaluate the mode of detection of 400 renal tumours as a prognostic factor compared with the usual clinical and pathological prognostic…”
Get full text

Absence of VHL gene alteration and high VEGF expression are associated with tumour aggressiveness and poor survival of renal-cell carcinoma by Patard, J-J, Rioux-Leclercq, N, Masson, D, Zerrouki, S, Jouan, F, Collet, N, Dubourg, C, Lobel, B, Denis, M, Fergelot, P

“…Background: The von Hippel–Lindau gene ( VHL ) alteration, a common event in sporadic clear-cell renal-cell carcinoma (CCRCC), leads to highly vascularised…”
Get full text

Sexual life of male patients with advanced renal cancer treated with angiogenesis inhibitors by Bessede, T., Massard, C., Albouy, B., Leborgne, S., Gross-Goupil, M., Droupy, S., Patard, J.-J., Fizazi, K., Escudier, B.

“…The advanced renal cell carcinoma (RCC) affects patients mainly ∼60 years of age and who may have an active sex life. The objective of the study was to…”
Get full text

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs by Beuselinck, B, Jean-Baptiste, J, Couchy, G, Job, S, De Reynies, A, Wolter, P, Théodore, C, Gravis, G, Rousseau, B, Albiges, L, Joniau, S, Verkarre, V, Lerut, E, Patard, J J, Schöffski, P, Méjean, A, Elaidi, R, Oudard, S, Zucman-Rossi, J

“…Background: Bone metastases (BMs) are associated with poor outcome in metastatic clear-cell renal carcinoma (m-ccRCC) treated with anti-vascular endothelial…”
Get full text

A preoperative clinical prognostic model for non‐metastatic renal cell carcinoma by Cindolo, L., De La Taille, A., Messina, G., Romis, L., Abbou, C.C., Altieri, V., Rodriguez, A., Patard, J.J.

“…Authors from Naples, Paris and Rennes describe their efforts to develop a model for the preoperative prediction of outcome for non‐metastatic renal cancer. It…”
Get full text

Is there a volume–outcome relationship for partial nephrectomy? by Couapel, J.-P., Bensalah, K., Bernhard, J.-C., Pignot, G., Zini, L., Lang, H., Rigaud, J., Salomon, L., Bellec, L., Soulié, M., Vaessen, C., Rouprêt, M., Jung, J.-L., Mourey, E., Bigot, P., Bruyère, F., Berger, J., Ansieau, J.-P., Gimel, P., Salome, F., Hubert, J., Pfister, C., Baumert, H., Timsit, M.-O., Méjean, A., Patard, J. J.

“…Objective To investigate the impact of hospital volume on partial nephrectomy indications and outcomes. Materials and methods Data were extracted from the…”
Get full text

Neoadjuvant targeted therapies in renal cell carcinoma by Bigot, P, Pignot, G, Bernhard, J-C, Patard, J-J

“…Targeted molecules are used in the treatment of metastatic kidney cancer. Their use before surgery could reduce tumor volume, facilitate surgical resection and…”
Get more information

CCAFU Recommendations 2013: Renal cancer by Patard, J-J, Baumert, H, Bensalah, K, Bernhard, J-C, Bigot, P, Escudier, B, Grenier, N, Hétet, J-F, Long, J-A, Méjean, A, Paparel, P, Richard, S, Rioux-Leclercq, N, Coloby, P, Soulié, M

“…The renal sub Committee of the CCAFU established guidelines for diagnosis, treatment, evaluation and standard of care for renal cell carcinoma. 2010 Guidelines…”
Get more information

Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR by Reix, B, Bernhard, J-C, Patard, J-J, Bigot, P, Villers, A, Suer, E, Vuong, N S, Verhoest, G, Alimi, Q, Beauval, J-B, Benoit, T, Nouhaud, F-X, Lenormand, C, Hamidi, N, Cai, J, Eto, M, Larre, S, El Bakhri, A, Ploussard, G, Hung, A, Koutlidis, N, Schneider, A, Carrouget, J, Droupy, S, Marchal, S, Doerfler, A, Seddik, S, Matsugasumi, T, Orsoni, X, Descazeaud, A, Pfister, C, Bensalah, K, Soulie, M, Gill, I, Flamand, V

“…Partial nephrectomy (PN) is recommended as first-line treatment for cT1 stage kidney tumors because of a better renal function and probably a better overall…”
Get more information

genitourinary tumours, non prostate Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC) by Ravaud, A., Motzer, R.J., Pandha, H.S., Staehler, M., George, D., Pantuck, A.J., Patel, A., Chang, Y.-H., Escudier, B., Donskov, F., Magheli, A., Carteni, G., Laguerre, B., Tomczak, P., Breza, J., Gerletti, P., Lin, X., Lechuga, M., Martini, J.-F., Patard, J.-J.

Get full text

Outcome of radical cystectomy for bladder cancer according to the disease type at presentation by Yiou, R., Patard, J.‐J., Benhard, H., Abbou, C.‐C., Chopin, D.K.

“…Objective To examine whether the outcome of cystectomy for invasive transitional cell carcinoma (TCC) of the bladder was influenced by the type of disease at…”
Get full text

Interleukin‐6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte–dendritic cell cross‐talk by Cabillic, F., Bouet‐Toussaint, F., Toutirais, O., Rioux‐Leclercq, N., Fergelot, P., De La Pintière, C. Thomas, Genetet, N., Patard, J.‐J., Catros‐Quemener, V.

“…Summary Anti‐tumour T cell response requires antigen presentation via efficient immunological synapse between antigen presenting cells, e.g. dendritic cells…”
Get full text